Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer

British Journal of Cancer

Volumn 113, Issue 4, 2015, Pages 603-610

  Rees, J ^a,b   Hurt, C N ^c   Gollins, S ^d   Mukherjee, S ^e   Maughan, T ^e   Falk, S J ^f   Staffurth, J ^c   Ray, R ^c   Bashir, N ^c   I Geh, J ^g   Cunningham, D ^h   Roy, R ⁱ   Bridgewater, J ^j   Griffiths, G ^c,k   SNixon, L ^c   Blazeby, J M ^a,b   Crosby, T ^l  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d GLAN CLWYD HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^g QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^l VELINDRE CANCER CENTRE   (United Kingdom)

more..

Author keywords

cancer; cetuximab; chemoradiotherapy; oesophgeal; patient reported outcomes

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; MONOCLONAL ANTIBODY;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DYSPHAGIA; ESOPHAGUS CANCER; FATIGUE; FOLLOW UP; HUMAN; INSOMNIA; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; XEROSTOMIA; CHEMORADIOTHERAPY; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROCEDURES; QUESTIONNAIRE;

ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84939265220     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.258     Document Type: Article

References (40)

1. Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N, Filiberti A, Flechtner H, Fleishman S, de Haes J, Kaasa S, Klee M, Rofe P, Schraub S, Sneeuw K, Sullivan M, Takeda F. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85: 365-376.
2. Ariga H, Nemoto K, Miyazaki S, Yoshioka T, Ogawa Y, Sakayauchi T, Jingu K, Miyata G, Onodera K, Ichikawa H, Kamei T, Kato S, Ishioka C, Satomi S, Yamada S. (2009). Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 75(2): 348-356.
3. Avery KN, Metcalfe C, Barham CP, Alderson D, Falk SJ, Blazeby JM. (2007). Quality of life during potentially curative treatment for locally advanced oesophageal cancer. Br J Surg. 94(11): 1369-1376.
4. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. (2008). The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 159(5): 997-1035.
5. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. (2007). Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 25(10): 1160-1168.
6. Blazeby JM, Alderson D, Farndon JR. (2000). Quality of life in patients with oesophageal cancer. Recent Results Cancer Res. 155: 193-204.
7. Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, Arraras J, Bottomley A, Vickery CW, Etienne PL, Alderson D. European Organisation for RTreatement of Cancer GQuality of Life G. (2003). Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 39(10): 1384-1394.
8. Blazeby JM, Sanford E, Falk SJ, Alderson D, Donovan JL. (2005). Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer. 103(9): 1791-1799.
9. Blazeby JM, Strong S, Donovan JL, Wilson C, Hollingworth W, Crosby T, Nicklin J, Falk SJ, Barham CP, Hollowood AD, Streets CG, Titcomb D, Krysztopik R, Griffin SM, Brookes ST. (2014). Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer. Br J Cancer. 111(2): 234-240.
10. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. CONSORT PRO Group. (2013). Reporting of patient-reported outcomes in randomized trials: The consort pro extension. JAMA. 309(8): 814-822.
11. Conroy T, Galais M-P, Raoul J-L, Bouché O, Gourgou-Bourgade S, Douillard J-Y, Etienne P-L, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A. (2014). Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/.ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 15(3): 305-314.
12. Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G. (2013). Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 14(7): 627-637.
13. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. The MAGIC Trial Participants. (2006). Perioperative Chemotherapy Versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med. 355(1): 11-20.
14. Derogar M, Orsini N, Sadr-Azodi O, Lagergren P. (2012). Influence of major postoperative complications on health-related quality of life among longterm survivors of esophageal cancer surgery. J Clin Oncol. 30(14): 1615-1619.
15. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. (2002). EORTC QLQ-C30 Scoring Manual. 2nd edn. (EORTC Publications: Brussels, Belgium
16. Finlay AY, Khan GK. (1994). Dermatology Life Quality Index (DLQI)-A simple practical measure for routine clinical use. Clin Exp Dermatol. 19(3): 210-216.
17. Food and Drug Administration. (2009). Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to support Labeling Claims. Food and Drug Administration, US Department of Health and Human Services: Rockville, MD, USA
18. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. (2007). Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-Analysis. Lancet Oncol. 8(3): 226-234.
19. Gillham CM, Aherne N, Rowley S, Moore J, Hollywood D, O'Byrne K, Reynolds JV. (2008). Quality of life and survival in patients treated with radical chemoradiation alone for oesophageal cancer. Clin Oncol (R Coll Radiol) 20(3): 227-233.
20. Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD. (2011). SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer. 11: 466.
21. Jacobs M, Macefield RC, Blazeby JM, Korfage IJ, van Berge Henegouwen MI, de Haes HC, Smets EM, Sprangers MA. (2012). Systematic review reveals limitations of studies evaluating health-related quality of life after potentially curative treatment for esophageal cancer. Qual Life Res. 22(7): 1787-1803.
22. Jacobs M, Macefield RC, Blazeby JM, Korfage IJ, van Berge Henegouwen MI, de Haes HC, Smets EM, Sprangers MA. (2013). Systematic review reveals limitations of studies evaluating health-related quality of life after potentially curative treatment for esophageal cancer. Qual Life Res. 22(7): 1787-1803.
23. Jacobs M, Macefield RC, Elbers RG, Sitnikova K, Korfage IJ, Smets EMA, Henselmans I, van Berge Henegouwen MI, de Haes JCJM, Blazeby JM, Sprangers MAG. (2014). Meta-Analysis shows clinically relevant and longlasting deterioration in health-related quality of life after esophageal cancer surgery. Qual Life Res. 23(4): 1155-1176.
24. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. (2011). Global cancer statistics. CA Cancer J Clin. 61(2): 69-90.
25. Kranzfelder M, Schuster T, Geinitz H, Friess H, Buchler P. (2011). Metaanalysis of neoadjuvant treatment modalities and definitive nonsurgical therapy for oesophageal squamous cell cancer. Br J Surg. 98(6): 768-783.
26. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. (2001). Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345(10): 725-730.
27. Malthaner RA, Collin S, Fenlon D. (2006). Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 3: CD001556.
28. MRC Oesophageal Cancer Working Party. (2002). Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 359(9319): 1727-1733.
29. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 16(1): 139-144.
30. Parameswaran R, Blazeby JM, Hughes R, Mitchell K, Berrisford RG, Wajed SA. (2010). Health-related quality of life after minimally invasive oesophagectomy. Br J Surg. 97(4): 525-531.
31. Parameswaran R, McNair A, Avery KN, Berrisford RG, Wajed SA, Sprangers MA, Blazeby JM. (2008). The role of health-related quality of life outcomes in clinical decision making in surgery for esophageal cancer: a systematic review. Ann Surg Oncol. 15(9): 2372-2379.
32. Rees JR, Blazeby JM, Fayers P, Friend EA, Welsh FK, John TG, Rees M. (2012). Patient-reported outcomes after hepatic resection of colorectal cancer metastases. J Clin Oncol. 30(12): 1364-1370.
33. Reynolds JV, McLaughlin R, Moore J, Rowley S, Ravi N, Byrne PJ. (2006). Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone. Br J Surg. 93(9): 1084-1090.
34. Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Burmeister B, Kelsen D, Niedzwiecki D, Schuhmacher C, Urba S, van de Velde C, Walsh TN, Ychou M, Jensen K. (2013). Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-Analysis combining individual patient and aggregate data. Eur J Cancer. 49(15): 3149-3158.
35. Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Jensen K. Group GEAM-A. (2013). Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 5: CD008107.
36. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. (2008). Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 26(7): 1086-1092.
37. Wong R, Malthaner R. (2006). Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 1: CD002092.
38. Yamashita H, Okuma K, Seto Y, Mori K, Kobayashi S, Wakui R, Ohtomo K, Nakagawa K. (2009). A retrospective comparison of clinical outcomes and quality of life measures between definitive chemoradiation alone and radical surgery for clinical stage II-III esophageal carcinoma. J Surg Oncol. 100(6): 435-441.
39. Yamashita H, Okuma K, Seto Y, Mori K, Kobayashi S, Wakui R, Ohtomo K, Nakagawa K. (2009). A retrospective comparison of clinical outcomes and quality of life measures between definitive chemoradiation alone and radical surgery for clinical stage II-III esophageal carcinoma. J Surg Oncol. 100(6): 435-441.
40. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P. (2011). Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 29(13): 1715-1721.